We are delighted to announce the launch of HyTest’s latest monoclonal antibodies (MAbs) targeting the nucleoprotein (NP) of influenza B virus, Cat. # 3IF18. The newly introduced MAbs, namely IB44, IB57, IB70, IB71, IB76, IB87, IB91 are derived from a diverse group of animals, including mouse, rat, sheep, and rabbit. All the MAbs, except those derived from mouse, have been transferred into the recombinant format with human IgG constant domains. The diversity of animal sources for immunization enables a broader range of options for your application platforms and meets various testing needs.  

These MAbs are particularly suitable for lateral flow (LF) assays, demonstrating sensitivity against the recombinant influenza B NP antigen below 0.5 ng/ml. They are also compatible with chemiluminescence immunoassay (CLIA) and enzyme immunoassay (EIA). Compared to our previous influenza B MAbs, the newly developed MAbs cover a wider range of influenza virus type B strains and show no cross-reactivity with influenza A NP. With the addition of these new mabs, we aim to provide an optimized solution for your needs in rapid and accurate assay development. For more information, please contact our Sales Team. 

Click below and you will be directed to the product page where you can request samples. 

If you're considering the development of a combination test kit that targets Influenza A, COVID-19, and RSV, we provide an extensive selection of products for infectious diseases.

Did you know our COVID-19 offerings can also detect the Pirola and Eris variants? Read more!

Reference: 

(1). Krammer, F., Smith, G.J.D., Fouchier, R.A.M. et al. Influenza. Nat Rev Dis Primers 4, 3 (2018).